Skip to main content
KBS_Icon_questionmark link-ico


Andreas Kimergård is a researcher in public health, alcohol and other emerging drug issues. For over a decade, he has worked on regional, national and international research studies to develop and implement effective health interventions into practice.

Since 2014, he has worked at the Addictions Department, King’s College London, where he is trial manager in the team responsible for delivering optimal methods of implementation of treatments for people with physical and mental comorbidities relating to alcohol (ARC Alcohol Theme, 2019–2024). This involves managing a  randomised controlled trial of assertive outreach treatment for people with frequent alcohol related attendances to hospital (AAOT Trial, 2016–2020). Prior to this, he worked as part of an EU–funded project on the use, misuse and dependence on codeine (CODEMISUSED, 2013–2016). He also worked on an EU–funded study which aimed to gain understanding of the supply of New Psychoactive Substances (NPS) on the internet (CASSANDRA, 2015–2017). He managed a trial to evaluate contingency management for alcohol relapse prevention and now serves as a member of the trial management group (ADAM Trial, 2016–2020).

In 2019, his work on ADAM and the Alcohol Assertive Outreach Treatment (AAOT) project won him the South London NIHR Clinical Research Network Researcher of the year award. The AAOT team also won a 2019 BMJ Award in the mental health category.

Prior to joining King’s College London, Andreas completed his PhD in Medicine at the Department of Public Health, Aarhus University, with a focus on the use of human enhancement drugs. Andreas has published extensively on alcohol and other drugs issues, including misused and falsified medicines and NPS with evidence and methods cited in reports published by the World Health Organization (WHO) and United Nations Office on Drugs and Crime (UNODC). Given his expertise in the public health issues related to NPS, Andreas was recently appointed to the list of experts for 2020–2023 used by the EU drug agency, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), for the assessment of risks posed by NPS across the EU.